digital health investment
The company offers a patient recruitment platform for clinical trials.
The company offers computer vision technology that enables humanoids and robots to perceive the world in 3D similar to how humans use their eyes and depth perception.
The company will use the funds to expand its technology and operations across Medicaid, Medicare Advantage and ACA marketplace plans in the U.S.
The funding boosts the Australia-based company's valuation to $465 million and brings its total raise to almost $100 million.
The funds will be used to expand the company's workforce and accelerate development of its AI-powered patient engagement platform, Assort OS.
The company will use the funds to scale nationally, broaden partnerships with payers and health systems, and expand into new neurological condition areas.
Telehealth company Caregility, hybrid cancer care company Daymark Health and virtual care company AmplifyMD also garnered funding.
The company will use the funds to expand Dreem Health, scale nationwide and advance its FDA-cleared sleep apnea technology.
The Series D funding brings the company’s total raise to $275 million and its valuation to more than $1 billion.
The company stated Capital Rx will still operate as its pharmacy benefits manager brand under Judi Health.